Date: 2018-08-07
Type of information: Nomination
Compound:
Company: Infinity Pharmaceuticals (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On August 7, 2018, Infinity Pharmaceuticals announced that it has appointed Samuel Agresta , M.D., M.P.H., as Chief Medical Officer where he will oversee global clinical development and regulatory affairs for the company.
- Dr. Agresta joins Infinity from Agios Pharmaceuticals, where he played a pivotal role in the development of the company's oncology programs, including Idhifa® and Tibsovo®, as Vice President and Head of Clinical Development. The drugs are both first-in-class, orally available, targeted medicines for the treatment of patients with acute myeloid leukemia that harbor IDH mutations. Prior to Agios, Dr. Agresta worked on the development of oncology therapeutics at Merrimack Pharmaceuticals and Genentech after spending ten years practicing academic medicine. He began his career at the Moffitt Cancer Center , where he served as Associate Medical Director in the Sarcoma Oncology Unit. Dr. Agresta earned an M.D. from Tulane University School of Medicine as well as an M.P.H. from Tulane University School of Public Health and Tropical Medicine .
Financial terms:
Latest news:
Is general: Yes
